DelveInsight’s, “Smallpox Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Smallpox pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Smallpox Pipeline Insight Report
- DelveInsight’s Smallpox Pipeline report depicts a robust space with 04+ active players working to develop 04+ pipeline therapies for Smallpox treatment.
- The leading Smallpox Companies include Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and others.
- The promising Smallpox therapies include FD MVA-BN, Vaccinia virus: ACAM2000 smallpox vaccine, MVA-BN® (IMVAMUNE), TPOXX, and others.
- The companies and academics are working to assess challenges and seek opportunities that could influence Smallpox R&D. The therapies under development are focused on novel approaches to treat/improve Smallpox.
Get an overview of the Smallpox Pipeline landscape @ Smallpox Emerging Therapies
Smallpox Overview
Smallpox is an acute contagious disease caused by the variola virus, a member of the orthopoxvirus family. It was one of the most devastating diseases known to humanity and caused millions of deaths before it was eradicated. Smallpox is a category A pathogen which are those organisms/biological agents that pose the highest risk to national security and public health because they can be easily disseminated or transmitted from person to person, result in high mortality rates and have the potential for major public health impact, might cause public panic and social disruption, and require special action for public health preparedness.
Latest Breakthroughs and Developments in the Smallpox Treatment Landscape
- Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2022. BCV is designed to improve treatment of viral infections by enhancing drug delivery to the intracellular site of viral replication. BCV effectively penetrates cells via its lipid conjugate, releasing the nucleotide analog cidofovir, which then acts to inhibit virus replication.
- TNX-801 is a novel, live virus vaccine grown in cell culture.1 Tonix is developing TNX-801 as a potential smallpox preventing vaccine for widespread immunization and national stockpile. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that Tonix believes it may lower toxicity and offer potential safety advantages over existing vaccinia-based vaccines, which have been associated with adverse side effects such as myocarditis/pericarditis.
- Brincidofovir (BCV) is an oral antiviral being developed for the treatment of smallpox under the U.S. Food and Drug Administration’s Animal Efficacy Rule, which allows for testing of investigational drugs in animal models to support effectiveness in diseases that are not ethical or feasible to study in humans. BCV is currently under review for approval at the U.S.
Smallpox Emerging Drugs
- Brincidofovir: Chimerix
- TNX-801: Tonix Pharmaceuticals Holding Corp
Get to know more information about Smallpox treatment therapies @ Smallpox Clinical Trials
Smallpox Pipeline Therapeutics Analysis
There are approx. 4+ key companies which are developing the therapies for Smallpox. The companies which have their Smallpox drug candidates in the most advanced stage, i.e. phase preregistration include, Chimerix.
DelveInsight’s Smallpox Pipeline Report covers around 4+ products under different phases of clinical development like-
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Discover more about therapy set to grab substantial Smallpox Pipeline landscape @ Smallpox Pipeline Therapeutics Assessment
Scope of the Smallpox Pipeline Report
- Coverage- Global
- Smallpox Companies- Chimerix, BioFactura, Tonix Pharmaceuticals Holding Corp, Bavarian Nordic A/S, ViRAZE, HK inno.N, and others
- Smallpox Therapies- FD MVA-BN, Vaccinia virus: ACAM2000 smallpox vaccine, MVA-BN® (IMVAMUNE), TPOXX, and others
- Smallpox Pipeline Assessment by Product Type
- Smallpox Pipeline Assessment by Stage and Product Type
- Smallpox Pipeline Assessment by Route of Administration
- Smallpox Pipeline Assessment by Stage and Route of Administration
- Smallpox Pipeline Assessment by Molecule Type
- Smallpox Pipeline Assessment by Stage and Molecule Type
Table of Content
- Introduction
- Executive Summary
- Smallpox: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Smallpox – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Smallpox Collaboration Deals
- Late Stage Products (Prergistration)
- Brincidofovir: Chimerix
- Preclinical and Discovery Stage Products
- IN-B002: HK inno.N
- Inactive Products
- Smallpox Key Companies
- Smallpox Key Products
- Smallpox- Unmet Needs
- Smallpox- Market Drivers and Barriers
- Smallpox- Future Perspectives and Conclusion
- Smallpox Analyst Views
- Smallpox Key Companies
- Appendix
Got Queries? Reach out for more information on the Smallpox Pipeline Report @ Smallpox Preclinical and Discovery Stage Products
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/